The purpose of this bulletin is to highlight the difference in cost between acetylcysteine and carbocisteine when used as mucolytics, and to raise awareness of savings which could be achieved within ICBs. The bulletin considers the potential budget impact to primary care prescribing budgets based on current prescribing of carbocisteine across the ICSs in the North East & Yorkshire region and Greater Manchester.

This publication was updated in February 2024 after the removal of the Price concession from carbocisteine. All prices stated are from the February 2024 Drug Tariff